AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7608705 — intervention group
Group type: EXPERIMENTAL
Intervention: Interictal SPECT
Number of subjects: 177
Study 1978477 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride (90-600 mg daily)
Number of subjects: 145
Study 1978477 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (5-45 mg daily)
Number of subjects: 145
Study 6768492 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microgram HOE 766 i.m.
Number of subjects: 5
Study 31817245 — intervention group
Group type: EXPERIMENTAL
Intervention: CuOx/CNF (copper oxide microelectrode arrays dispersed within carbon nanofiber paste)
Number of subjects: 0
Study 31817245 — intervention group
Group type: EXPERIMENTAL
Intervention: CuOx/CNF
Number of subjects: 0
Study 26658434 — intervention group
Group type: EXPERIMENTAL
Intervention: Uphill sprint training (UST) - 10 x 10 sec sprints with 60s recovery on a 7% gradient for six weeks, twice weekly
Number of subjects: 14
Study 26658434 — intervention group
Group type: COMPARATOR
Intervention: Normal activity (Control)
Number of subjects: 14
Study 25862743 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 3501
Study 23665733 — intervention group
Group type: EXPERIMENTAL
Intervention: Negatively-charged polystyrene microspheres (NCM)
Number of subjects: 58
Study 23665733 — intervention group
Group type: COMPARATOR
Intervention: Control (saline soaks)
Number of subjects: 58
Study 22929843 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound with nerve stimulation
Number of subjects: 70
Study 22929843 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulation
Number of subjects: 70
Study 19638366 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive blood pressure lowering targeting SBP <130 mmHg using a combination of amlodipine/valsartan and additional antihypertensive medications as needed.
Number of subjects: 228
Study 19638366 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure lowering targeting SBP <140 mmHg using a combination of amlodipine/valsartan and additional antihypertensive medications as needed.
Number of subjects: 228
Study 19352059 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/d MK-4 for 4 weeks
Number of subjects: 40
Study 19352059 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 40
Study 16389774 — intervention group
Group type: COMPARATOR
Intervention: Whitening strips (10% hydrogen peroxide)
Number of subjects: 28
Study 16389774 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-brushing mouthrinse (2% hydrogen peroxide)
Number of subjects: 28
Study 12469001 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrabenazine (TBZ) at a final mean dose of 62.5 ± 37.4 mg/day (range 25‐150)
Number of subjects: 19
Study 9469353 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified chemotherapy (V-ICE every 3 weeks)
Number of subjects: 300
Study 9469353 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy (V-ICE every 4 weeks)
Number of subjects: 300
Study 9469353 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF) 250 microg/m2/d for 14 days between chemotherapy cycles
Number of subjects: 300
Study 9469353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 7879258 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor-specific transfusions (DST) with continuous Aza immunosuppression
Number of subjects: 163
Study 2229451 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (750 mg every 12 hours for 5 days before and 24 hours after quinidine administration)
Number of subjects: 7
Study 2229451 — intervention group
Group type: COMPARATOR
Intervention: Quinidine sulfate (400 mg administered alone)
Number of subjects: 7
Study 361794 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 30 mg daily
Number of subjects: 24
Study 361794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 361794 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 24
Study 12577250 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous amifostine
Number of subjects: 54
Study 12577250 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amifostine
Number of subjects: 54
Study 12577250 — intervention group
Group type: COMPARATOR
Intervention: No amifostine
Number of subjects: 54
Study 31819309 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supplementation and fortification of breast milk (FMS-Aptamil-DANON) during NICU hospitalization, with protein added when milk reached 100 cc/kg/day, increased by 20 cc/kg/day until 150-180 cc/kg/day, stopped when weight reached 1500 grams.
Number of subjects: 36
Study 31819309 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supplementation and fortification of breast milk (FMS-Aptamil-DANON) during NICU hospitalization.
Number of subjects: 36
Study 31819309 — intervention group
Group type: COMPARATOR
Intervention: Control group fed similar to intervention group without protein supplementation.
Number of subjects: 36
Study 29408510 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (before manufacturing change)
Number of subjects: 0
Study 29408510 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (after manufacturing change)
Number of subjects: 0
Study 29408510 — intervention group
Group type: COMPARATOR
Intervention: Nonclinical assessments
Number of subjects: 0
Study 26553744 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 302
Study 26553744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 24691852 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.5 % bupivacaine hydrochloride
Number of subjects: 60
Study 24691852 — intervention group
Group type: COMPARATOR
Intervention: Topical 0.9 % NaCl (saline)
Number of subjects: 60
Study 24691852 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine hydrochloride infiltration
Number of subjects: 60
Study 23214214 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing PEEP trial
Number of subjects: 60
Study 23214214 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreasing PEEP trial
Number of subjects: 60
Study 23214214 — intervention group
Group type: COMPARATOR
Intervention: PEEP/FiO2 tables
Number of subjects: 60
Study 20870099 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate carotid endarterectomy (CEA)
Number of subjects: 3120
Study 20870099 — intervention group
Group type: COMPARATOR
Intervention: Deferred carotid procedure
Number of subjects: 3120
Study 17566091 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg rhTSH
Number of subjects: 29
Study 17566091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 17566091 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study 15607836 — intervention group
Group type: EXPERIMENTAL
Intervention: High level of cocaine use during the 2-week lead-in period
Number of subjects: 50
Study 15607836 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking as the primary route of cocaine use
Number of subjects: 50
Study 15607836 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level of cocaine use during the 2-week lead-in period
Number of subjects: 50
Study 12383289 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 200
Study 12383289 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam
Number of subjects: 200
Study 12383289 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of piroxicam and dexamethasone
Number of subjects: 200
Study 10024065 — intervention group
Group type: EXPERIMENTAL
Intervention: BDI scores > or =10 (depressed women)
Number of subjects: 896
Study 10024065 — intervention group
Group type: COMPARATOR
Intervention: BDI scores <10 (nondepressed women)
Number of subjects: 896
Study 10024065 — intervention group
Group type: EXPERIMENTAL
Intervention: BDI scores > or =10 (depressed men)
Number of subjects: 896
Study 10024065 — intervention group
Group type: COMPARATOR
Intervention: BDI scores <10 (nondepressed men)
Number of subjects: 896
Study 10024065 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased BDI scores (both genders)
Number of subjects: 896
Study 7790649 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed single-tone suppressors
Number of subjects: 6
Study 2349410 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium (3 X 5 mmol granulate orally on the day preceding menstruation and on the first and second day of the cycle)
Number of subjects: 32
Study 2349410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 2349410 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium
Number of subjects: 32
Study 208825 — intervention group
Group type: EXPERIMENTAL
Intervention: pivmecillinam
Number of subjects: 0
Study 208825 — intervention group
Group type: COMPARATOR
Intervention: amoxycillin
Number of subjects: 0
Study 30701349 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosexual counseling (6 weekly sessions, 90 to 120 min each)
Number of subjects: 118
Study 30701349 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 118
Study 29979423 — intervention group
Group type: EXPERIMENTAL
Intervention: AHE with real-time ultrasound imaging feedback (group B)
Number of subjects: 20
Study 29979423 — intervention group
Group type: COMPARATOR
Intervention: Conventional feedback (group A)
Number of subjects: 20
Study 27149770 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidential feedback of data and tailor-made problem-solving workshops
Number of subjects: 0
Study 27149770 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 24568229 — intervention group
Group type: EXPERIMENTAL
Intervention: Jump-landing task and knee-laxity assessment 3 to 5 days after the onset of menses
Number of subjects: 20
Study 24568229 — intervention group
Group type: EXPERIMENTAL
Intervention: Jump-landing task and knee-laxity assessment within 3 days of a positive ovulation test
Number of subjects: 20
Study 21667354 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy quality assurance (QA) for JCOG 0303
Number of subjects: 106
Study 21667354 — intervention group
Group type: COMPARATOR
Intervention: Institutions enrolling <7 patients
Number of subjects: 106
Study 20568090 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor task (reaction time) in patients with PD
Number of subjects: 23
Study 20568090 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual learning task in patients with PD
Number of subjects: 23
Study 20568090 — intervention group
Group type: EXPERIMENTAL
Intervention: Reaction times in patients with PD
Number of subjects: 23
Study 20568090 — intervention group
Group type: COMPARATOR
Intervention: Motor task (reaction time) in healthy controls
Number of subjects: 23
Study 20568090 — intervention group
Group type: COMPARATOR
Intervention: Visual learning task in healthy controls
Number of subjects: 23
Study 17320962 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin therapy (antioxidants plus zinc)
Number of subjects: 20000000
Study 17320962 — intervention group
Group type: COMPARATOR
Intervention: No vitamin therapy
Number of subjects: 20000000
Study 15667826 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed limit increased from 50 to 70 km/h
Number of subjects: 19
Study 15667826 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed limit increased from 70 to 80 km/h
Number of subjects: 19
Study 11179081 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methionine loading
Number of subjects: 0
Study 11179081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9735650 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment without drainage
Number of subjects: 59
Study 9735650 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment with tube drainage
Number of subjects: 59
Study 9735650 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 59
Study 8138773 — intervention group
Group type: EXPERIMENTAL
Intervention: Interview or postal questionnaire before invitation for breast screening
Number of subjects: 3291
Study 8138773 — intervention group
Group type: COMPARATOR
Intervention: Control group (no interview)
Number of subjects: 3291
Study 8138773 — intervention group
Group type: EXPERIMENTAL
Intervention: Health behaviours and attitudes
Number of subjects: 3291
Study 8138773 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitudes, beliefs, and intentions
Number of subjects: 3291
Study 3395914 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 2.0 mg given every 6 h
Number of subjects: 1
Study 3395914 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine
Number of subjects: 1
Study 3395914 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol
Number of subjects: 1
Study 3395914 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 1
Study 31131103 — intervention group
Group type: EXPERIMENTAL
Intervention: Education package delivered to mothers (nutrition, stimulation, hygiene education)
Number of subjects: 155
Study 31131103 — intervention group
Group type: COMPARATOR
Intervention: Routine health care (control group)
Number of subjects: 155
Study 28634703 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoperistaltic side-to-side anastomosis
Number of subjects: 0
Study 28634703 — intervention group
Group type: COMPARATOR
Intervention: Antiperistaltic side-to-side anastomosis
Number of subjects: 0
Study 26085538 — intervention group
Group type: EXPERIMENTAL
Intervention: Video review with an orthopaedic traumatologist (intervention group, n=8)
Number of subjects: 15
Study 26085538 — intervention group
Group type: COMPARATOR
Intervention: No video review (control group, n=7)
Number of subjects: 15
Study 26085538 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 15
Study 23443254 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole treatment in compliant patients
Number of subjects: 63
Study 23443254 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole treatment in non-compliant patients
Number of subjects: 63
Study 20731735 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 739
Study 20731735 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 739
Study 19951540 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative-pressure wound therapy (NPWT) with interrupted suction under a pressure of -16.63 kPa for 24 hours or continuous suction under a pressure of -10.64 kPa for 24 hours.
Number of subjects: 67
Study 19951540 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (CT) with petrolatum gauze overlaid with isotonic saline gauze and dry gauze.
Number of subjects: 67
Study 17029523 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbond Plus Self‐Etching adhesive
Number of subjects: 30
Study 17029523 — intervention group
Group type: COMPARATOR
Intervention: Transbond XT conventional adhesive
Number of subjects: 30
Study 12523456 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 3.0 mg/kg
Number of subjects: 10
Study 12523456 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg
Number of subjects: 10
Study 12523456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 11142415 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins (vitamins C and E and beta-carotene)
Number of subjects: 121
Study 11142415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 9109903 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (39 mg/day)
Number of subjects: 22
Study 9109903 — intervention group
Group type: EXPERIMENTAL
Intervention: Benztropine (3.0 mg/day)
Number of subjects: 22
Study 7942174 — intervention group
Group type: EXPERIMENTAL
Intervention: Opening of the lamina terminalis and Lilliequist's membrane
Number of subjects: 197
Study 3281872 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth (120 mg administered through an intraoesophageal tube four times a day) + Cimetidine (800 mg at night)
Number of subjects: 20
Study 3281872 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine alone (800 mg at night)
Number of subjects: 20
Study 3281872 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth + Cimetidine
Number of subjects: 20
Study 3281872 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine alone
Number of subjects: 20
Study 31314661 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-Based Multimedia Intervention (WBMI)
Number of subjects: 160
Study 31314661 — intervention group
Group type: COMPARATOR
Intervention: Educational Pamphlet
Number of subjects: 160
Study 29973170 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally produced maternal food-based supplementation
Number of subjects: 87
Study 27998216 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use in SELECT
Number of subjects: 2
Study 27998216 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use in PCPT
Number of subjects: 2
Study 27998216 — intervention group
Group type: EXPERIMENTAL
Intervention: Black ethnicity in SELECT
Number of subjects: 2
Study 27998216 — intervention group
Group type: EXPERIMENTAL
Intervention: Black ethnicity in PCPT
Number of subjects: 2
Study 25915944 — intervention group
Group type: EXPERIMENTAL
Intervention: PET/CT-guided dose escalation chemoradiotherapy (group C)
Number of subjects: 67
Study 25915944 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-guided dose escalation chemoradiotherapy (group B)
Number of subjects: 67
Study 25915944 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemoradiotherapy (group A)
Number of subjects: 67
Study 23422371 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 202
Study 23422371 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 202
Study 23422371 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 202
Study 23422371 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 202
Study 19785620 — intervention group
Group type: COMPARATOR
Intervention: Placebo-controlled studies
Number of subjects: 140
Study 19785620 — intervention group
Group type: EXPERIMENTAL
Intervention: Median study duration
Number of subjects: 140
Study 19785620 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriasis Area and Severity Index score
Number of subjects: 140
Study 19785620 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life measure
Number of subjects: 140
Study 19785620 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical company sponsorship
Number of subjects: 140
Study 18382182 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (400 mg/d or maximum tolerated dose)
Number of subjects: 62
Study 18382182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 16362532 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg methylprednisolone injection
Number of subjects: 0
Study 16362532 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg methylprednisolone injection
Number of subjects: 0
Study 16362532 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg methylprednisolone injection
Number of subjects: 0
Study 16362532 — intervention group
Group type: EXPERIMENTAL
Intervention: One or two injections of methylprednisolone
Number of subjects: 0
Study 16362532 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (20 mg, 40 mg, 60 mg)
Number of subjects: 0
Study 11914933 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT (uracil and tegafur) administered at 400 mg/day for 2 years
Number of subjects: 289
Study 11914933 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgery alone)
Number of subjects: 289
Study 9865705 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m2 every 3 weeks
Number of subjects: 326
Study 9865705 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin 75 mg/m2 every 3 weeks
Number of subjects: 326
Study 9865705 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel in patients with resistant disease
Number of subjects: 326
Study 9865705 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin in patients with resistant disease
Number of subjects: 326
Study 9865705 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 326
Study 9865705 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 326
Study 7613277 — intervention group
Group type: EXPERIMENTAL
Intervention: Homoeopathy
Number of subjects: 24
Study 7613277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2136976 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (1.0, 2.0, and 4.0 micrograms/kg)
Number of subjects: 30
Study 2136976 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (0.1, 0.2, and 0.4 micrograms/kg)
Number of subjects: 30
Study 109635 — intervention group
Group type: EXPERIMENTAL
Intervention: High nitrogen elemental diet (300 calories tid)
Number of subjects: 30
Study 109635 — intervention group
Group type: COMPARATOR
Intervention: Standard diet with usual between‐meal feedings
Number of subjects: 30
Study 109635 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritionally supported patients
Number of subjects: 30
Study 109635 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 6295270 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftizoxime 2, 3, or 4 g intravenously
Number of subjects: 13
Study 31881916 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 94
Study 31881916 — intervention group
Group type: COMPARATOR
Intervention: Control (psycho-education and relaxation)
Number of subjects: 94
Study 29595707 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 32
Study 29595707 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.15 mg/kg bolus dose, then 0.2 mg/kg per hour infusion)
Number of subjects: 32
Study 26697854 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 171
Study 26697854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 24622715 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice daily)
Number of subjects: 173
Study 24622715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173